Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a research note issued to investors on Thursday. The firm set a "hold" rating on the medical research company's stock.

Separately, D. Boral Capital reissued a "buy" rating and set a $10.00 target price on shares of Cytosorbents in a report on Tuesday, April 1st. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Cytosorbents currently has an average rating of "Moderate Buy" and an average price target of $4.67.

Cytosorbents Stock Performance

Shares of CTSO traded up $0.02 during trading hours on Thursday, reaching $0.99. 50,924 shares of the company traded hands, compared to its average volume of 143,699. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The business has a fifty day moving average price of $1.06 and a 200-day moving average price of $1.04. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61. The stock has a market capitalization of $61.91 million, a P/E ratio of -2.75 and a beta of 1.17.

Remove Ads

Cytosorbents (NASDAQ:CTSO - Get Free Report) last announced its quarterly earnings data on Monday, March 31st. The medical research company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.04. The business had revenue of $9.20 million for the quarter, compared to analyst estimates of $10.09 million. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. Equities analysts anticipate that Cytosorbents will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTSO. Millennium Management LLC purchased a new stake in shares of Cytosorbents during the 4th quarter worth about $30,000. Renaissance Technologies LLC grew its holdings in Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock valued at $80,000 after purchasing an additional 8,400 shares during the period. Northern Trust Corp grew its holdings in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock valued at $83,000 after purchasing an additional 16,701 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Cytosorbents in the fourth quarter valued at approximately $99,000. Finally, Geode Capital Management LLC raised its stake in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after buying an additional 32,415 shares during the period. Hedge funds and other institutional investors own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.